טוען...
Cost of Refractory Crohn’s Disease Before and After Ustekinumab Utilization
BACKGROUND: Crohn’s disease (CD) is associated with major health services utilization and costs. Between 2012 and 2015, ustekinumab was used off-label in Quebec, Canada for treatment of refractory CD. AIMS: We assessed the direct medical cost of adult CD patients in the 1-year pre- and 1-year postus...
שמור ב:
| הוצא לאור ב: | J Can Assoc Gastroenterol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Oxford University Press
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7678737/ https://ncbi.nlm.nih.gov/pubmed/33241178 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz025 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|